Effect of CTLA4-Ig on severe asthma (ECSA) study ; Double blind, placebo controlled, phase IIa trial of CTLA4-Ig (abatacept) on severe asthma

Phase 2

• Conditions: Severe asthma

• Registration Number: JPRN-UMIN000016283
• Lead Sponsor: ational Hospital Organization, Sagamihara National Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-02-01
• Study Completion: 2016-04-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Administration of abatacept in the past. Rheumatoid arthritis. Respiratory disorders other than asthma. Current malignancy or past history of (within 5 years) malignancy. Other clinically serious health problems. Active infectious diseases or psoriasis. Those who are pregnant, under-lactation, or desire pregnancy. Administration of live vaccine within past 3 months or during the trial period or those who desire live vaccine within 3 months from the end of the trial. Omalizumab use within past 3 months. History or suspicion of alcohol or drug abuse within past 2 years. Enrollment in other clinical trials within past 3 months. Other conditions that doctors consider not eligible.

Study & Design

• Study Type: Interventional
• Study Design: Not specified